Key Highlights

  • Novanta (NASDAQ:NOVT) shares fell 15.26% on November 10, 2026, after fourth-quarter adjusted Earnings guidance of USD 0.91 to USD 0.96 per share came in below a consensus near USD 1.02.
  • Novanta's third-quarter Revenue rose 23.1% to USD 305.0 million and adjusted earnings rose to USD 1.05 per share, but GAAP Operating Margin fell to 4.6%.
  • Goosehead Insurance fell 15.64% after reporting only preliminary third-quarter results because of pending restatements tied to a Securities and Exchange Commission comment letter.
  • Goosehead said revenue and profit were better than expected, but core revenue grew less than hoped as Texas insurance prices fell more than expected.

Novanta: Growth Was Not the Problem

Novanta (NASDAQ:NOVT) supplies precision motion, photonics and medical components used in robotics, surgical systems and industrial automation. Its third-quarter revenue rose 23.1% to USD 305.0 million, with organic growth of 9.9% and the rest from acquisitions, including Riverpoint Medical, the largest deal in its history. Customer bookings rose 29% and Backlog reached USD 543 million. Adjusted earnings rose to USD 1.05 per share from USD 0.87, and adjusted EBITDA rose 38.3% to USD 80.3 million. The concern was the outlook and reported profitability. Fourth-quarter guidance calls for revenue of USD 306 million to USD 312 million and adjusted earnings of USD 0.91 to USD 0.96 per share, well below a consensus near USD 1.02. GAAP operating margin fell to 4.6% from 8.8%, and GAAP earnings dropped to USD 0.05 per share as Acquisition costs and Amortisation rose. Net Debt climbed to about USD 689.4 million after the Riverpoint purchase. The shares fell as much as 17.6% during the session before closing down 15.26%. The reaction showed that investors were more focused on near-term earnings power than on the strength of bookings and backlog.

Goosehead: An Accounting Overhang

Goosehead Insurance, a franchise-based personal lines insurance agency, faced a different kind of problem. Instead of full results, it published preliminary third-quarter figures because it is preparing restatements of earlier financial statements tied to a comment letter from the Securities and Exchange Commission. The company said total revenue and profit were better than expected. However, core revenue, which reflects commissions on new and renewed policies, grew less than hoped, partly because insurance prices in Texas fell more than expected, and improving customer retention only partly offset that. Investors typically react sharply to restatements because they raise questions about the reliability of past numbers and can delay filings, which is why the shares fell 15.64% despite the better-than-expected preliminary figures.

What to Watch for Both

For Novanta (NASDAQ:NOVT), the key questions are whether integration of Riverpoint lifts margins in 2027, whether medical Demand stays strong and how quickly debt can be reduced. Management expects reported revenue growth of more than 15% in 2027, and full-year 2026 guidance calls for revenue of USD 1.135 billion to USD 1.14 billion with organic growth of about 7%. For Goosehead, the priorities are the timing and scope of the restatement, whether it affects revenue recognition on renewals, and whether Texas pricing pressure eases. Both stocks also fell on a day when the hot October Inflation report pushed yields higher, which weighed on Growth Stocks with premium valuations. Clarity on guidance in one case and on accounting in the other will be needed before investors regain confidence.

Where Things Stand

Novanta (NASDAQ:NOVT) fell 15.26% on November 10, 2026 after guiding fourth-quarter adjusted earnings of USD 0.91 to USD 0.96 per share, below a consensus near USD 1.02, despite 23.1% revenue growth. Goosehead Insurance fell 15.64% after issuing only preliminary third-quarter results because of restatements tied to an SEC comment letter. Guidance credibility and accounting clarity are the respective next tests.